Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Related Articles
Anumana’s ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status
Medical Product Outsourcing: Artificial intelligence (AI)-driven healthtech company, Anumana has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI-enhanced, ECG-based pulmonary hypertension (PH) early detection algorithm.…May 23, 2022
Anumana: Interview With CEO Maulik Nanavaty About The AI-Driven Health Technology Company
Anumana is a company that is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout…May 22, 2025
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG Data
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG DataCAMBRIDGE, Mass, June 27, 2024 Anumana, a leading AI-driven health technology company…June 27, 2024
AI transforms smartwatch ECG signals into a diagnostic tool for heart failure
Mayo Clinic News Network: Two health tech advances are at the heart of a study published in Nature Medicine: an app and backend infrastructure to let patients remotely share smartwatch…November 14, 2022